TABLE 3

Associations between ADIPOQ genotypes and the risk of CVD

SNPsCVD
OR (95% CI)
Case subjects (%)Control subjects (%)CrudePAdjusted*P
−11365
    CC158 (56.6)355 (52.0)1.01.0
    CG102 (36.6)283 (41.5)0.81 (0.60–1.09)0.160.76 (0.55–1.04)0.09
    GG19 (6.8)44 (6.5)0.97 (0.55–1.72)0.920.93 (0.50–1.72)0.81
−4034
    AA128 (46.2)299 (44.4)1.01.0
    AC107 (38.6)307 (45.6)0.81 (0.60–1.10)0.180.90 (0.65–1.25)0.52
    CC42 (15.2)67 (10.0)1.46 (0.94–2.27)0.091.71 (1.06–2.78)0.03
    Recessive1.62 (1.07–2.45)0.021.81 (1.14–2.85)0.01
−3964
    AA190 (68.6)449 (66.3)1.01.0
    AG80 (28.9)201 (29.7)0.94 (0.69–1.28)0.701.06 (0.76–1.48)0.74
    GG7 (2.5)27 (4.0)0.61 (0.26–1.43)0.260.72 (0.29–1.80)0.48
+45
    TT204 (76.7)529 (78.7)1.01.0
    TG + GG62 (23.3)143 (21.3)1.12 (0.80–1.58)0.501.22 (0.84–1.76)0.29
+276
    GG159 (56.8)374 (54.7)1.01.0
    GT104 (37.1)258 (37.7)0.95 (0.71–1.27)0.720.94 (0.68–1.29)0.70
    TT17 (6.1)52 (7.6)0.77 (0.43–1.37)0.370.65 (0.34–1.23)0.18
  • *

    * Adjusted for age, BMI, smoking, alcohol consumption, physical activity, HbA1c, history of hypertension and of hypercholesterolemia, diabetes duration, and postmenopausal hormone use.